NO990643D0 - Tienopyrimidiner - Google Patents

Tienopyrimidiner

Info

Publication number
NO990643D0
NO990643D0 NO990643A NO990643A NO990643D0 NO 990643 D0 NO990643 D0 NO 990643D0 NO 990643 A NO990643 A NO 990643A NO 990643 A NO990643 A NO 990643A NO 990643 D0 NO990643 D0 NO 990643D0
Authority
NO
Norway
Prior art keywords
thienopyrimidine
Prior art date
Application number
NO990643A
Other languages
English (en)
Norwegian (no)
Other versions
NO990643L (no
Inventor
Jonas Rochus
Pierre Schelling
Franz-Werner Kluxen
Maria Christadler
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO990643L publication Critical patent/NO990643L/no
Publication of NO990643D0 publication Critical patent/NO990643D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO990643A 1996-08-12 1999-02-11 Tienopyrimidiner NO990643D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19632423A DE19632423A1 (de) 1996-08-12 1996-08-12 Thienopyrimidine
PCT/EP1997/004139 WO1998006722A1 (de) 1996-08-12 1997-07-30 Thienopyrimidine

Publications (2)

Publication Number Publication Date
NO990643L NO990643L (no) 1999-02-11
NO990643D0 true NO990643D0 (no) 1999-02-11

Family

ID=7802392

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990643A NO990643D0 (no) 1996-08-12 1999-02-11 Tienopyrimidiner

Country Status (29)

Country Link
US (1) US6110920A (hu)
EP (1) EP0920431B1 (hu)
JP (1) JP4405593B2 (hu)
KR (1) KR100502271B1 (hu)
CN (1) CN1081638C (hu)
AR (1) AR009052A1 (hu)
AT (1) ATE233265T1 (hu)
AU (1) AU725227B2 (hu)
BR (1) BR9711062A (hu)
CA (1) CA2263561C (hu)
CZ (1) CZ287772B6 (hu)
DE (2) DE19632423A1 (hu)
DK (1) DK0920431T3 (hu)
ES (1) ES2191192T3 (hu)
HK (1) HK1021731A1 (hu)
HU (1) HUP0001607A3 (hu)
IL (1) IL128504A (hu)
NO (1) NO990643D0 (hu)
NZ (1) NZ334600A (hu)
PL (1) PL190174B1 (hu)
PT (1) PT920431E (hu)
RU (1) RU2199541C2 (hu)
SI (1) SI0920431T1 (hu)
SK (1) SK282823B6 (hu)
TR (1) TR199900308T2 (hu)
TW (1) TW359672B (hu)
UA (1) UA55421C2 (hu)
WO (1) WO1998006722A1 (hu)
ZA (1) ZA977156B (hu)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819023A1 (de) * 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
AU3453900A (en) * 1999-03-30 2000-10-23 Nippon Soda Co., Ltd. Thienopyrimidine compounds and salts thereof and process for the preparation of the same
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
DE10031585A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 2-Aminoalkyl-thieno[2,3-d]pyrimidine
AU2001290311A1 (en) * 2000-09-29 2002-04-08 Nippon Soda Co., Ltd. Thienopyrimidine compounds and their salts and process for preparation of both
BR0206853A (pt) * 2001-02-02 2004-01-13 Merck Patent Ges Mit Beschroen Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antagonistas de receptor de endotelina ou tienopirimidinas e antagonistas de receptor de endotelina
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US6849638B2 (en) * 2001-04-30 2005-02-01 Bayer Pharmaceuticals Corporation 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of pde7b-mediated diseases and conditions
WO2003035653A1 (fr) * 2001-10-26 2003-05-01 Nippon Soda Co.,Ltd. Compose pyridothienopyrimidine et son sel
US7153412B2 (en) 2001-12-28 2006-12-26 Kabushiki Kaisha Toyota Chuo Kenkyusho Electrodes, electrochemical elements, gas sensors, and gas measurement methods
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
AR044743A1 (es) * 2002-09-26 2005-10-05 Nihon Nohyaku Co Ltd Herbicida, metodo de emplearlo, derivados de tienopirimidina sustituida,compuestos intermediarios, y procedimientos que se utilizan para producirlos,
GB0320300D0 (en) * 2003-08-29 2003-10-01 Cancer Rec Tech Ltd Pyrimidothiophene compounds
DE10351436A1 (de) * 2003-11-04 2005-06-09 Merck Patent Gmbh Verwendung von Thienopyrimidinen
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) * 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
JP5366269B2 (ja) 2007-09-14 2013-12-11 ジャンセン ファーマシューティカルズ， インコーポレイテッド． １，３−二置換４−（アリル−ｘ−フェニル）−１ｈ−ピリジン−２−オン
ES2356032T3 (es) 2007-09-14 2011-04-04 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 4-fenil-3,4,5,6-tetrahidro-2h,1'h-[1,4']bipiridinil-2'-onas 1,3'-disustituidas.
KR20100080597A (ko) * 2007-09-14 2010-07-09 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된-４-페닐-1ｈ-피리딘-2-온
CN101861316B (zh) * 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
US8586733B2 (en) 2008-07-31 2013-11-19 Senomyx, Inc. Processes and intermediates for making sweet taste enhancers
CN102143955B (zh) 2008-09-02 2013-08-14 Omj制药公司 作为代谢型谷氨酸受体调节剂的3-氮杂二环[3.1.0]己烷衍生物
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
EP2373649B1 (en) 2008-11-28 2013-01-23 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
SG10201402250TA (en) 2009-05-12 2014-07-30 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
JP5707390B2 (ja) 2009-05-12 2015-04-30 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2814996C (en) 2010-11-08 2019-10-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
AU2012284091B2 (en) 2011-07-19 2015-11-12 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EP2880031B1 (en) 2012-08-06 2020-06-17 Firmenich Incorporated Sweet flavor modifier
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
CN109999025A (zh) 2014-01-21 2019-07-12 詹森药业有限公司 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途
NZ722385A (en) 2014-01-21 2019-11-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
MX2016014384A (es) 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
EP3394056B1 (en) 2015-12-22 2021-04-14 Shy Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
JP7514005B2 (ja) * 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
CN112703193A (zh) 2018-08-07 2021-04-23 弗门尼舍公司 5-取代的4-氨基-1H-苯并[c][1,2,6]噻二嗪2,2-二氧化物及其制剂和用途
CN116178374A (zh) * 2023-01-13 2023-05-30 河北医科大学 小电导钙激活钾离子通道激动剂及其合成和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4196207A (en) * 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds

Also Published As

Publication number Publication date
AU725227B2 (en) 2000-10-12
DK0920431T3 (da) 2003-06-02
SK282823B6 (sk) 2002-12-03
EP0920431B1 (de) 2003-02-26
RU2199541C2 (ru) 2003-02-27
PT920431E (pt) 2003-07-31
NZ334600A (en) 2000-07-28
PL331538A1 (en) 1999-07-19
HK1021731A1 (en) 2000-06-30
CN1081638C (zh) 2002-03-27
TR199900308T2 (xx) 1999-04-21
ES2191192T3 (es) 2003-09-01
DE59709404D1 (en) 2003-04-03
IL128504A (en) 2003-01-12
IL128504A0 (en) 2000-01-31
CA2263561A1 (en) 1998-02-19
JP4405593B2 (ja) 2010-01-27
ATE233265T1 (de) 2003-03-15
WO1998006722A1 (de) 1998-02-19
NO990643L (no) 1999-02-11
SI0920431T1 (en) 2003-08-31
CZ44899A3 (cs) 1999-05-12
KR100502271B1 (ko) 2005-07-22
AR009052A1 (es) 2000-03-08
SK16499A3 (en) 1999-06-11
EP0920431A1 (de) 1999-06-09
DE19632423A1 (de) 1998-02-19
AU4203597A (en) 1998-03-06
TW359672B (en) 1999-06-01
HUP0001607A3 (en) 2002-09-30
CZ287772B6 (en) 2001-01-17
JP2000516223A (ja) 2000-12-05
UA55421C2 (uk) 2003-04-15
BR9711062A (pt) 1999-08-17
PL190174B1 (pl) 2005-11-30
US6110920A (en) 2000-08-29
CN1227560A (zh) 1999-09-01
ZA977156B (en) 1998-02-19
HUP0001607A2 (hu) 2000-10-28
KR20000029932A (ko) 2000-05-25
CA2263561C (en) 2007-02-20

Similar Documents

Publication Publication Date Title
NO990643D0 (no) Tienopyrimidiner
ATE208395T1 (de) Thiophenopyrimidine
ATE262512T1 (de) Arylalkanoylpyridazine
ID19474A (id) Turunan tiazola
NO20002702D0 (no) Tienopyrimidiner
ATE208773T1 (de) Chinoxalindione
ID18095A (id) Turunan tetrahidrokinolin
ATE353652T1 (de) Östroprogestatives antikonzeptionsmittel
BR9703563A (pt) Hidromancal
BR9703835A (pt) Hidromancal
UA1360S (uk) Електронно-лазерний тир
ATE267568T1 (de) Epithese
BR7601310U (pt) Microlivro
BR9606252A (pt) Cromosauna
BR7600030U (pt) Cinturita
BR7601419U (pt) Mourao
BR9602174A (pt) Lecton massoterapeutico
BR7601548U (pt) Tomadamax
BR7601720U (pt) Paraglayder
BR7600260U (pt) Multi-morsa
BR7602320U (pt) Supedânea
BR7603088U (pt) Kitgeométrico
BR7603126U (pt) Bate - estacas
BR7603147U (pt) Simborgueup
BR7603380U (pt) Abratporta

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application